Skip to main
IMTX
IMTX logo

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV is positioned favorably within the biotechnology sector due to its innovative ACTengine platform, which enhances the logistics of solid tumor cell therapies, potentially leading to better patient outcomes and shorter manufacturing times. The company is currently focused on its late-stage asset, anzu-cel, which is undergoing a pivotal Phase 3 study (SUPRAME) demonstrating promising preliminary efficacy data and addressing a significant unmet medical need within the cancer treatment market, valued at approximately $2 billion in the U.S. Additionally, the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to anzu-cel, providing regulatory advantages that may accelerate its path to market and strengthen investor confidence.

Bears say

Immatics NV faces a challenging outlook due to underwhelming clinical data for its lead product, Brenetafusp, which demonstrated only an 11% objective response rate and a 56% disease control rate in a critical melanoma indication. The company’s financial projections are vulnerable to downward revisions that may arise from ongoing risks, including potential R&D, regulatory, and commercial setbacks, along with competitive pressures and disappointing pipeline developments. Furthermore, a scenario where the SUPRAME trial fails to meet its primary endpoint could severely impair valuations, potentially leading to no perceived value for the company's other therapeutic pipeline assets.

Immatics NV (IMTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.